Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06053294 · ClinicalTrials.gov registry record · NA

Neural and Metabolic Factors in Carbohydrate Reward

A NA study of Carbohydrate Metabolism, sponsored by Virginia Polytechnic Institute and State University.

Recruiting
Registry status
NA
Development phase
64
Enrollment target
1
Study location

NCT06053294: Recruiting NA study of Carbohydrate Metabolism, sponsored by Virginia Polytechnic Institute and State University.

NCT06053294 is a NA study of Carbohydrate Metabolism that is actively recruiting participants, run by Virginia Polytechnic Institute and State University. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06053294, a NA study of Carbohydrate Metabolism, is actively recruiting participants, sponsored by Virginia Polytechnic Institute and State University.

RECRUITING
Registry status
NA
Development phase
64 participants
Enrollment target
1
Study location

Study Summary

Dietary factors contributed to nearly 50% of all cardiometabolic deaths in the US in 2012, making it one of the leading causes of preventable death in the US, second only to tobacco use. Human diets and food choices can't help but be influenced by the ubiquitous availability of processed foods of high-energy density and low nutrient content, consumption of which can lead to obesity, type II diabetes, heart disease, and other types of metabolic dysfunction. Surprisingly, food reinforcement does not rely on perceived energy density. Rather food reinforcement is associated with actual energy density and therefore, on an implicit knowledge of caloric content. That implicit knowledge must have a neural signature and a mechanism by which the gut communicates nutritive value to the brain. There is evidence, at least for fat and carbohydrates, that these pathways are separable, but terminate in a common neural structure, the dorsal striatum or caudate. This could be one mechanism by which modern processed foods high in both fat and carbohydrate are so sought after and readily consumed, In fact, when experimentally tested, fat and carbohydrate combinations were more reinforcing calorie for calorie than fat or carbohydrates alone and the level of reinforcement correlated with activity in reward- related brain areas. Beyond simple reinforcing value, it is known from the literature on drugs of abuse that the faster a drug is arrives at the brain, the higher it's abuse potential, however, little is known about how the kinetics of nutrient excursion influence food preference, choice, and brain activity. This project aims to test this specifically for carbohydrate reward.

Primary Outcome

Subjective ratings of liking of flavors used in the intervention will be assessed at baseline and after the intervention. The generalized Labeled Magnitude Scale will be used. The scale is anchored by descriptors of "Most Disliked Sensation Imaginable" and "Most Liked Sensation Imaginable" at the lower and upper ends, respectively. The score is determined by the place on the scale participants select (range of scale is 0-100). An increase in score from baseline to post-intervention indicates an

Conditions Studied

Interventions

  • OTHER CS- Beverage
  • OTHER CS+Fast
  • OTHER CS+Slow

Study Locations (1)

Virginia

  • Fralin Biomedical Research Institute at VTC - Roanoke

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2023-05-01
Est. Completion 2029-05-01
Phase NA

What NCT06053294 shows while recruiting

NCT06053294 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Carbohydrate Metabolism appearing as the primary indexed condition, and to 3 interventions - of which CS- Beverage is the first listed.

NCT06053294 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT06053294 about?

NCT06053294 is a clinical study titled "Neural and Metabolic Factors in Carbohydrate Reward". Dietary factors contributed to nearly 50% of all cardiometabolic deaths in the US in 2012, making it one of the leading causes of preventable death in the US, second only to tobacco use. Human diets and food choices can't help but be influenced by the ubiquitous availability of processed foods of hi...

What is the current status of trial NCT06053294?

This trial is currently recruiting. It is a NA study. The enrollment target is 64 participants. The study started on 2023-05-01. Estimated completion is 2029-05-01.

What conditions does trial NCT06053294 study?

This clinical trial studies the following conditions: Carbohydrate Metabolism.

What interventions are being tested in trial NCT06053294?

The interventions under investigation include: CS- Beverage (OTHER), CS+Fast (OTHER), CS+Slow (OTHER).

Who is sponsoring clinical trial NCT06053294?

This trial is sponsored by Virginia Polytechnic Institute and State University, which has 104 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06053294 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT06053294's enrollment target sits among peer trials

64 1147th of 2000 higher than 844 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06053294, the US trial registry maintained by the National Library of Medicine. NCT06053294 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.